Department of Rheumatology, Toulouse University Hospital, Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Paul Sabatier University, Toulouse, France.
CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse; INSERM UMR1291 - CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France.
Clin Exp Rheumatol. 2024 Nov;42(11):2141-2149. doi: 10.55563/clinexprheumatol/48440j. Epub 2024 Oct 17.
To compare the humoral response after a SARS-CoV-2 infection in an inflammatory rheumatic disease population with a healthy control population in a case-control study.
Cases: between March and September 2021, all consecutive unvaccinated patients followed for rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA) in 16 hospitals in France were systematically screened with a SARS-CoV-2 serological test. Patients with a positive test were included in the COVID-RIC-2 cohort.
between June and July 2020, healthcare professionals working in the Toulouse University Hospital were screened with a SARS-CoV-2 serological test. Those with a positive test were included in the COVID-BIOTOUL cohort and matched to those from COVID-RIC-2 by age, sex and time-sampling on infection date.
total SARS-CoV-2 antibody titres were centrally measured and compared.
95 patients from COVID-RIC-2 (mean age 49 years, 76% females, median delay of COVID infection: 149 days) including 48 RA, 33 SpA and 14 PsA were compared to 95 matched controls. Globally, there was no significant difference of SARS-CoV-2 antibody titres between both populations: 155 Binding Antibody Units (BAU) (IQR:7-376) in COVID-RIC-2 vs. 120 BAU (IQR:35-320) in COVID-BIOTOUL. There was a trend towards higher antibody titres in patients from COVID-RIC-2 with severe COVID-19 symptoms. In COVID-RIC-2, there was no impact of age, sex, time-sampling or underlying disease on antibody titres and patients taking glucocorticoids, abatacept or rituximab trended toward having lower antibody titres after COVID-19 infection.
This study provides reassuring data on humoral response after COVID-19 infection in patients treated with disease-modifying anti-rheumatic drugs.
在一项病例对照研究中，比较炎症性风湿病患者和健康对照组在 SARS-CoV-2 感染后的体液反应。
病例：2021 年 3 月至 9 月期间，法国 16 家医院连续筛查所有未接种疫苗的类风湿关节炎（RA）、脊柱关节炎（SpA）或银屑病关节炎（PsA）患者，进行 SARS-CoV-2 血清学检测。检测结果阳性的患者纳入 COVID-RIC-2 队列。
2020 年 6 月至 7 月期间，在图卢兹大学医院工作的医护人员进行 SARS-CoV-2 血清学检测。检测结果阳性的患者纳入 COVID-BIOTOUL 队列，并按感染日期的年龄、性别和时间进行匹配。
中心测量并比较了总 SARS-CoV-2 抗体滴度。
COVID-RIC-2 队列包括 95 例患者（平均年龄 49 岁，76%为女性，COVID 感染的中位延迟时间为 149 天），其中 48 例为 RA，33 例为 SpA，14 例为 PsA，与 95 例匹配的对照组进行比较。总体而言，两组人群的 SARS-CoV-2 抗体滴度无显著差异：COVID-RIC-2 队列为 155 结合抗体单位（BAU）（IQR：7-376），COVID-BIOTOUL 队列为 120 BAU（IQR：35-320）。COVID-RIC-2 队列中 COVID-19 症状严重的患者抗体滴度有升高趋势。在 COVID-RIC-2 队列中，年龄、性别、时间采样或基础疾病对抗体滴度无影响，服用糖皮质激素、阿巴西普或利妥昔单抗的患者 COVID-19 感染后抗体滴度有下降趋势。
本研究为接受疾病修饰抗风湿药物治疗的患者 COVID-19 感染后的体液反应提供了令人安心的数据。
